Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791478 · ClinicalTrials.gov registry record · Phase 1
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
A Phase 1 study of HER2-Negative Breast Cancer and Stage IV Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 2
- Study locations
NCT01791478 is a Phase 1 study of HER2-Negative Breast Cancer and Stage IV Breast Cancer that is active but no longer recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 46 participants, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01791478, a Phase 1 study of HER2-Negative Breast Cancer and Stage IV Breast Cancer, is active but no longer recruiting, sponsored by Vanderbilt-Ingram Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer. The PI3K inhibitor BYL719 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving the PI3K inhibitor BYL719 together with letrozole may kill more tumor cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG letrozole
- DRUG PI3K inhibitor BYL719
- OTHER pharmacological studies
Study Locations (2)
Massachusetts
- Massachusetts General Hospital, Dana-Farber Cancer Institute - Boston
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-04 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791478
The ClinicalTrials.gov registry entry for NCT01791478 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01791478 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01791478 about?
NCT01791478 is a clinical study titled "BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer". This phase I trial studies the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer. The PI3K inhibitor BYL719 may stop the growth of tumor cells by blocking some of the proteins needed...
What is the current status of trial NCT01791478?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2013-04. Estimated completion is 2025-02-28.
What conditions does trial NCT01791478 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer, Stage IV Breast Cancer, Recurrent Breast Cancer, Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma.
What interventions are being tested in trial NCT01791478?
The interventions under investigation include: laboratory biomarker analysis (OTHER), letrozole (DRUG), PI3K inhibitor BYL719 (DRUG), pharmacological studies (OTHER).
Who is sponsoring clinical trial NCT01791478?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01791478 being conducted?
This trial has 2 study locations across Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.